Compare Novo Nordisk A/S (NVO) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs United States Natural Gas Fund — how do they compare? Novo Nordisk A/S trades at $46.2 (market cap $207.85B), while United States Natural Gas Fund trades at $10.2. The key difference: Novo Nordisk A/S pays a 3.81% dividend while United States Natural Gas Fund pays none, and Novo Nordisk A/S is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| NVO | UNG | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Commodities - Energy |
52-Week High | $63.98 | $16.90 |
52-Week Low | $35.29 | $9.63 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
UNG, the United States Natural Gas Fund, trades at $10.23, up 0.89% on the day, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The fund tracks natural gas futures, with recent news highlighting steady prices amid weather-driven demand shifts and geopolitical tensions affecting commodity markets. Key support and resistance cluster around $10, indicating a critical price zone.
The outlook for UNG hinges on natural gas supply-demand dynamics, with EIA forecasting record highs in 2026, but risks include volatility from weather patterns and Middle East conflicts. Investment appeal lies in exposure to energy themes, though the fund's structure as a futures tracker may lead to divergence from spot prices, as noted in comparative analyses with equity-based ETFs like FCG.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
